©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. Nov 10, 2010; 1(1): 1-2
Published online Nov 10, 2010. doi: 10.5306/wjco.v1.i1.1
What is the purpose of launching World Journal of Clinical Oncology?
Lian-Sheng Ma, World Series Journals, Baishideng Publishing Group Co., Limited, Beijing 100025, China
Author contributions: Ma LS solely contributed to this paper.
Correspondence to: Lian-Sheng Ma, President and Editor-in-Chief, World Series Journals, Baishideng Publishing Group Co., Limited, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China. firstname.lastname@example.org
Telephone: +86-10-59080036 Fax: +86-10-85381893
Received: September 6, 2010
Revised: October 19, 2010
Accepted: October 26, 2010
Published online: November 10, 2010
I am very pleased to announce that the first issue of World Journal of Clinical Oncology (World J Clin Oncol, WJCO, online ISSN 2218-4333, DOI: 10.5306), whose preparatory work was initiated on December 20, 2009, will be published on November 10, 2010. The WJCO Editorial Board has now been established and consists of 315 distinguished experts from 33 countries. What is the purpose of launching WJCO? And what is the scope and how are the columns designed?
The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the “priority” and “copyright” of innovative achievements published, as well as evaluating research performance and academic levels. To realize these desired attributes of a journal and create a well-recognized journal, the following four types of personal benefits should be maximized.
MAXIMIZATION OF PERSONAL BENEFITS
The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others.
Maximization of the benefits of editorial board members
The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers’ names and affiliations along with the article they reviewed in the journal to acknowledge their contribution.
Maximization of the benefits of authors
Since WJCO is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from WJCO official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading.
Maximization of the benefits of readers
Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion.
Maximization of the benefits of employees
It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal[2,3]. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.
CONTENTS OF PEER REVIEW
In order to guarantee the quality of articles published in the journal, WJCO usually invites three experts to comment on the submitted papers. The contents of peer review include: (1) whether the contents of the manuscript are of great importance and novelty; (2) whether the experiment is complete and described clearly; (3) whether the discussion and conclusion are justified; (4) whether the citations of references are necessary and reasonable; and (5) whether the presentation and use of tables and figures are correct and complete.
The aim of WJCO is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of oncology. WJCO covers etiology, epidemiology, evidence-based medicine, informatics, diagnostic imaging, endoscopy, tumor recurrence and metastasis, tumor stem cells, radiotherapy, chemotherapy, interventional radiology, palliative therapy, clinical chemotherapy, biological therapy, minimally invasive therapy, physiotherapy, psycho-oncology, comprehensive therapy, oncology-related traditional medicine, integrated Chinese and Western medicine, and nursing. WJCO covers tumors in various organs/tissues, including the female reproductive system, bone and soft tissue, respiratory system, urinary system, endocrine system, skin, breast, nervous system, head and neck, digestive system, and hematologic and lymphatic system. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to oncology, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.
The columns in the issues of WJCO will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide Guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in oncology; (9) Brief Articles: To briefly report the novel and innovative findings in oncology; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in WJCO, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of oncology; and (13) Guidelines: To introduce consensuses and guidelines reached by international and national academic authorities worldwide on the research oncology.
Peer reviewers: Athanassios Argiris, MD, FACP, Professor of Medicine, Associate Chief for Multidisciplinary Clinics, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Medical Director, Aerodigestive Cancers Program, University of Pittsburgh Cancer Institute, Co-Director, Lung Cancer Center, University of Pittsburgh Medical Center, 5150 Centre Avenue, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, United States; Hengmi Cui, PhD, Assistant Professor, Center for Epigenetics and Division of Molecular Medicine, Johns Hopkins University School of Medicine, 855 N Wolfe Street/572 Rangos Building, Baltimore, MD 21205, United States
S- Editor Cheng JX E- Editor Ma WH